Latest Media Releases for Huntington\'s Disease
Prana receives FDA Orphan Drug Designation for PBT2 for Huntington Disease
Prana Biotechnology (ASX:PBT) has today announced the US Food and Drug Administration (FDA) has granted Orphan Drug designation to PBT2 for the treatment of Huntington Disease.
World leader in movement disorders Professor Ira Shoulson joins Prana board
Professor Ira Shoulson will join Prana Biotechnology’s Board of Directors as a non-Executive Director.
Prana Completes Phase 2 Huntington Disease Trial with PBT2
Prana Biotechnology (NASDAQ:PRAN; ASX:PBT) today announced the successful completion of Reach2HD, a phase 2 clinical trial in patients with early to mid-stage Huntington disease. The Company expects to announce the results arising from the trial in October.
Prana presents new benchmark test to assess Huntington’s Disease patients in clinical trials
Prana Biotechnology has unveiled a world first, patient-reported outcomes study for Huntington’s Disease (HD) in a poster presentation at the 17th Annual Congress of Parkinson’s Disease and Movement Disorders being held in Sydney this week.
Prana Completes Recruitment in Huntington Trial
Prana Biotechnology today announced that it has completed recruitment in the Reach2HD Phase IIa clinical trial using PBT2 in patients with Huntington Disease (HD).
Journal of Huntington’s Disease Publishes Benefits of PBT2
Prana Biotechnology today announced that the Journal of Huntington’s Disease has in its December, 2012 edition, published data showing the benefits of PBT2 in Huntington Disease*. The paper describes PBT2’s ability to inhibit the development of the symptoms and pathological features of Huntington Disease in pre-clinical transgenic animal models.
Prana Provides Huntington Disease Trial Update in conjunction with the Huntington Study Group Annual Conference
Prana Biotechnology today reported on its progress in the Reach2HD trial, following a presentation by the Ms Dianne Angus, Prana’s Chief Operating Officer, at the Huntington Study Group Annual Conference held in Seattle this past weekend.
Prana’s PBT2 presented at the Huntington’s Disease Society of America National Convention: Prana’s ‘Reach2HD’ Phase II trial on track
Prana Biotechnology today announced that an update on Prana’s Phase 2 clinical trial in Huntington disease (HD) was presented at the HDSA annual National Convention held in Las Vegas, Nevada over the weekend. Professor Ira Shoulson, Professor of Neurology, Pharmacology and Human Science and Director, Program for Regulatory Science & Medicine at Georgetown University spoke to the ‘Reach2HD’ trial objectives and potential future of PBT2 as a novel therapeutic strategy for the treatment of HD.
Prana Comments on Archives of Neurology Publication Which Highlights Critical Role of Brain Metals in Huntington Disease Progression: MGH team publishes data that supports the use of PBT2 in Huntington disease
Prana Biotechnology today commented on the publication of new data of relevance to the current clinical trial, testing Prana’s PBT2 as a treatment for Huntington disease.